Key Highlights
- Net product sales were USD 35.25 million, compared with USD 38.21 million.
- Net loss was USD 5.0 million, or USD 0.03 per share.
- Acute care net product sales increased 22.5% to USD 15.1 million.
- Gross profit was 74.6% of sales, compared with 68.8% a year earlier.
Heron Therapeutics, Inc. (NASDAQ:HRTX) reported third quarter 2026 net product sales of USD 35.25 million, compared with USD 38.21 million in the third quarter of 2025. Estimates for the quarter stood at EPS of negative USD 0.03 and Revenue of USD 37.50 million. The net loss was USD 5.0 million, or USD 0.03 per share, compared with a net loss of USD 17.5 million, or USD 0.10 per share, a year earlier.
Loss from operations was USD 1.67 million, compared with USD 4.09 million.
Acute Care and Oncology Sales
Acute care net product sales were USD 15.1 million, an increase of USD 2.8 million, or 22.5%. Oncology net product sales were USD 20.1 million, a decrease of USD 5.7 million, or 22.2%. For the nine months, acute care net product sales increased USD 10.8 million, or 32.4%, to USD 44.1 million, and oncology net product sales decreased USD 17.5 million, or 21.6%, to USD 63.5 million. Total nine-month net product sales were USD 107.6 million, compared with USD 114.3 million.
The company's filing describes ZYNRELEF as the first and only modified-release local anesthetic classified by the FDA as an extended-release product. Since April 1, 2025, ZYNRELEF has been reimbursed in the hospital outpatient setting through inclusion in the NOPAIN Act.
Margins and Operating Expenses
Cost of product sales was USD 8.96 million, or 25.4% of sales, compared with USD 11.91 million, or 31.2%. The company tied the decrease to a USD 1.7 million reduction in inventory reserves and a USD 1.1 million effect from fewer units sold. Gross Profit was 74.6% of sales, compared with 68.8%. For the nine months, gross profit was 71.0% compared with 73.6%.
Research and development expenses were USD 3.1 million, compared with USD 3.5 million. General and administrative expenses were USD 12.3 million, compared with USD 14.0 million, and sales and Marketing expenses were USD 12.5 million, compared with USD 12.9 million.
Liquidity and Nine Month Results
Cash, cash equivalents and short-term investments were USD 23.4 million at September 30, 2026. The accumulated Deficit was USD 2.0 billion. For the nine months, the net loss was USD 18.6 million, or USD 0.10 per share, compared with USD 17.2 million, or USD 0.11 per share. Nine-month loss from operations was USD 8.5 million compared with USD 2.6 million, and sales and marketing expenses were USD 41.0 million compared with USD 36.8 million.
The filing states that the company has incurred significant operating losses and negative cash flows from operations, and that it has financed operations primarily through issuances of common stock, convertible notes and warrants, product sales and debt financings.
Acute Care, Oncology and Cash
Heron's net product sales of USD 35.25 million split between acute care, which grew 22.5% to USD 15.1 million, and oncology. Gross profit was 74.6% of sales, the cash balance was USD 23.4 million, and the filing notes that ZYNRELEF Vial Access Needle replaced the vented vial spike following FDA approval in September 2024.






Please wait processing your request...